Hsbc Holdings PLC Sells 48,147 Shares of Axon Enterprise, Inc $AXON

Hsbc Holdings PLC lowered its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 24.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 145,041 shares of the biotechnology company’s stock after selling 48,147 shares during the quarter. Hsbc Holdings PLC’s holdings in Axon Enterprise were worth $82,482,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Axon Enterprise by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after buying an additional 53,060 shares during the period. Geode Capital Management LLC raised its holdings in shares of Axon Enterprise by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after acquiring an additional 35,544 shares during the period. Baillie Gifford & Co. lifted its position in Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after acquiring an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC lifted its position in Axon Enterprise by 11.6% in the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after acquiring an additional 167,095 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in Axon Enterprise by 326.9% in the 4th quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after purchasing an additional 1,179,038 shares during the period. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 3.2%

Axon Enterprise stock opened at $410.03 on Tuesday. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91. The company has a fifty day simple moving average of $414.43 and a 200 day simple moving average of $484.39. The company has a market cap of $33.05 billion, a P/E ratio of 164.67, a price-to-earnings-growth ratio of 7.70 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The firm had revenue of $807.35 million for the quarter, compared to analysts’ expectations of $778.90 million. During the same period in the previous year, the firm posted $1.47 EPS. The company’s revenue for the quarter was up 33.7% on a year-over-year basis. Research analysts anticipate that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, insider Elizabeth Reid Coughlin sold 1,554 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the completion of the transaction, the insider directly owned 34,024 shares in the company, valued at $16,501,640. This trade represents a 4.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Joshua Isner sold 13,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the transaction, the president directly owned 169,125 shares in the company, valued at $82,609,106.25. This trade represents a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 38,989 shares of company stock valued at $19,090,083 in the last ninety days. Insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on AXON shares. Craig Hallum reiterated a “buy” rating and set a $820.00 target price on shares of Axon Enterprise in a report on Wednesday, February 25th. Weiss Ratings raised Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. UBS Group decreased their price objective on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Zacks Research raised Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Finally, Barclays cut their target price on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.